Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers

Antiviral Therapy

Volumn 12, Issue 5, 2007, Pages 789-796

  Schöller Gyüre, Monika ^a   Kakuda, Thomas N ^b   Sekar, Vanitha ^b   Woodfall, Brian ^a   De Smedt, Goedele ^a   Lefebvre, Eric ^b   Peeters, Monika ^a   Hoetelmans, Richard M ^a  

^a Research and Development   (Belgium)

^b Tibotec Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; ETRAVIRINE; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT;

ADULT; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; REFERENCE VALUES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SULFONAMIDES;

EID: 34547780413     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827-843.
2. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [updated 2006 October 10; cited 2007 July 11]. Available from http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf
3. De Meyer S, Azijn H, Surleraux D, et al. TMC114/r, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49:2314-2321.
4. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395-402.
5. Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007; 21:F11-F18.
6. Clotet B, Bellos N, Molina JM, et al.; POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178.
7. Molina JM, Cohen C, Katlama C, et al.; on Behalf of the TMC 114-C208 and -C215 Study Groups. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007. In press.
8. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:4680-4686.
9. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005; 79:12773-12782.
10. Gazzard BG, Pozniak AL, Rosenbaum W, et al. An open-label assessment of TMC125 - a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003; 17:F49-F54.
11. Gruzdev B, Rakhmanova A, Doubovskaya E, et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral-naive, HIV-1 infected subjects. AIDS 2003; 17:2487-2494.
12. The TMC125-C223 Writing Group. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS 2007; 21:F1-F10.
13. Cohen C, Steinhart CR, Ward DJ, et al. Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223. 16th International AIDS Conference. 13-18 August 2006, Toronto, Canada. Abstract TUPE0061.
14. Prezista™ (darunavir). Prescribing information. 2006. Tibotec Inc., Yardley, PA, USA.
15. Sekar V, Kestens D, Spinosa-Guzman S, et al. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol 2007; 47:479-484.
16. Sekar V, Spinosa-Guzman S, Lefebvre E, Hoetelmans R. Clinical pharmacology of TMC114 - a new protease inhibitor. 16th International AIDS Conference. 13-18 August 2006, Toronto, Canada. Abstract TUPE0083.
17. 14C-labelled TMC125 in healthy volunteers. 8th International Workshop of Clinical Pharmacology. 16-18 April 2007, Budapest, Hungary. Abstract 78.
18. Raoof A, Mannens G, Mamidi R, et al. In vivo metabolism and mass balance of the anti-HIV compound TMC125 in laboratory animals and healthy volunteers. AAPS Annual Meeting and Exposition. October 28-November 2 2006, San Antonio, TX, USA. Abstract M1342.
19. Kakuda TN, Schöller-Gyüre M, Woodfall BJ, et al. TMC125 in combination with other medications: summary of drug-drug interactions. 8th International Congress on Drug Therapy in HIV Infection. 12-16 November 2006, Glasgow, UK. Abstract PL5.2.
20. Schöller-Gyüre M, Leemans R, Vyncke V, et al. Effect of food on the oral bioavailability of the Phase III formulation of TMC125. 7th International Workshop of Clinical Pharmacology. 20-22 April 2006, Lisbon, Portugal. Abstract 80.
21. Bouche MP, Michielsen L, Piot M, Timmerman P. Swift and simultaneous determination of darunavir (TMC114) and ritonavir in human plasma using LC-MS/MS. 17th International Mass Spectrometry Conference. 27 August-1 September 2006, Prague, Czech Republic. Abstract TuP-042.
22. Schöller-Gyüre M, Debroye C, Woodfall B, et al. Pharmacokinetic evaluation of the interaction between TMC125 and tenofovir disoproxil fumarate. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 2006, San Francisco, CA, USA. Abstract A-371.
23. Kakuda TN, Schöller-Gyüre M, Peeters M, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of TMC125 in HIV-infected patients with non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI) resistance: TMC125-C223. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA
24. Boffito M, Winston A, Jackson A, et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high level viral resistance. AIDS 2007; 21:1449-1455.
25. Montaner J, Harris M, Kakuda T, et al. Combination of TMC114/r and TMC125 in patients with multidrug resistant HIV. 16th International AIDS Conference. 13-18 August 2006, Toronto, Canada. Abstract THPE0136.
26. Hsu A, Granneman GR, Bertz RJ. Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35:275-291.
27. Faucette SR, Wang H, Hamilton GA, et al. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 2004; 32:348-358.
28. Williams LA, O'Dea R, Weinberg M, et al. High incidence of rash associated with amprenavir (APV) during a pharmacokinetic (PK) interaction trial in HIV-negative, healthy volunteers. 13th International AIDS Conference. 9-14 July 2000, Durban, South Africa. Abstract WePeB4252.
29. Montaner J, Domingo P, Junod P, et al. Safety and tolerability of TMC125 in 3-class-experienced HIV-infected patients: 24-week primary analysis of trial TMC125-C203. European AIDS Conference. 17-20 November 2005, Dublin, Ireland. Abstract LBPS3/7B.